Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler(Johannes Gutenberg University Mainz), Yung‐Jue Bang(Seoul National University), Zev A. Wainberg(University of California, Los Angeles), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Matthew R. Silver(Merck KGaA, Darmstadt (Germany)), Arinilda Campos Bragagnoli(Hospital de Câncer de Barretos), Gina M. Vaccaro(Oregon Health & Science University), Toshimi Takano(The Cancer Institute Hospital), Sara Lonardi(Istituto Oncologico Veneto), Antonio Cubillo Gracián(Hospital Universitario HM Sanchinarro), Mikhail Dvorkin(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Hasan Şenol Çoşkun(Akdeniz University), Min‐Hee Ryu(Ulsan College), Rachel Wong(Box Hill Hospital), Janet Hong(Merck KGaA, Darmstadt (Germany)), Huiling Xiong(Merck KGaA, Darmstadt (Germany)), Marina Nechaeva(Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser), Narikazu Boku(Tokyo Medical University), Alina Muntean(Institute of Oncology Prof. Dr. Ion Chiricuta), Howard Safran(Brown University)
Cited by 222
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k